Aragon Pharmaceuticals, Inc. Announces First Patient Dosed in Phase I Study of ARN-810 in Estrogen Receptor Positive Breast Cancer
4/4/2013 9:22:28 AM
More...
|
Aragon Pharmaceuticals, Inc. Announces Key Strategic Hire
2/11/2013 9:25:19 AM
More...
|
Aragon Pharmaceuticals, Inc. Wins Key Legal Ruling Against Medivation, Inc. (MDVN)
1/4/2013 7:20:44 AM
More...
|
Aragon Pharmaceuticals, Inc. Snags $50 Million Series D
10/4/2012 6:18:41 AM
More...
|
Aragon Pharmaceuticals, Inc. Announces Clinical Results from Ongoing Phase II Trial Confirming Robust Anti-Tumor Activity and Tolerability of ARN-509 in Three Different Patient Populations of Castration Resistant Prostate Cancer
10/1/2012 10:54:43 AM
More...
|
Aragon Pharmaceuticals, Inc. Raises $50 Million
10/1/2012 7:24:06 AM
More...
|
Aragon Pharmaceuticals, Inc. Announces Appointment of Faheem Hasnain as Independent Director
8/28/2012 10:49:42 AM
More...
|
Aragon Pharmaceuticals, Inc. Nabs $42 Million, Targets Hormone-Driven Cancers
3/6/2012 6:33:37 AM
More...
|
Aragon Pharmaceuticals, Inc. to Present at the 10th Annual Biotechnology Industry Organization (BIO) Investor Forum on October 26
10/20/2011 12:38:03 PM
More...
|
Aragon Pharmaceuticals, Inc. Doses First Patient in Phase 1/2 Clinical Trial of ARN-509 for Castration-Resistant Prostate Cancer
8/9/2010 9:55:20 AM
More...
|
|